Assertio Agrees to $125 Million All-Cash Buyout by Garda Therapeutics
Assertio is being bought by Garda for $18/share + possible bonus if Sprix hits goals; deal closes June 2026, company goes private.
/ 352 items
#XY Event-Driven Stocks↓
Plus Therapeutics Stock Jumps After FDA Orphan Drug Win for Kids’ Rare Brain Tumors
Plus Therapeutics’ REYOBIQ gets FDA orphan drug status for rare kids’ brain tumors.
ANI Pharmaceuticals Stock Jumps After FDA OKs New Generic Heart Drug
ANI Pharma shares jump as it launches FDA-approved generic Monoket to prevent chest pain from heart disease.
Oscar Health CEO Buys $11.9 Million of Stock
Oscar Health CEO bought $11.9M in shares after stock payout, showing strong confidence. Shares jumped.
Insmed Discontinues Brensocatib HS Program After Phase 2b CEDAR Study Misses All Endpoints
Insmed’s HS drug failed to beat placebo in a mid-stage trial, though it was safe. Development for this condition has been stopped.
Gilead’s Third Deal of 2026: $3.15B Buyout of ADC Specialist Tubulis
Gilead buys German biotech Tubulis for $3.15B to boost cancer-fighting “smart” drugs called ADCs. Deal closes Q2 2026.